CellType

The agentic drug company. We simulate human biology.

Y CombinatorWinter 2026ActiveHealthcareDrug Discovery and Delivery

What they do

Problem

Drug discovery is slow, expensive, and error-prone due to limited ability to accurately model human biology and run end-to-end discovery efficiently.

Solution

CellType uses AI agents and biological foundation models that simulate human biology to automate and accelerate the full drug discovery pipeline and identify validated treatment signals.

Who it's for

Pharmaceutical companies and biotech R&D teams (including top pharma) use it to discover and validate new drug targets and therapies.

Founders

David van Dijk

Co-Founder & CEO

Co-Founder & CEO of CellType (W26). Yale Professor, 11,000+ citations. Built biological foundation models with Google. Building the agentic drug company.

LinkedIn · X

Ivan Vrkic

Co-Founder

Co-Founder @ CellType (W26). ML @ Yale & EPFL. Building the next-generation agentic drug company. Co-developed our core technology Cell2Sentence at Yale and published at ICML. Previously led large-scale foundation model training at a biotech startup and built software to control CERN's Large Hadron Collider.